{"id":"bimatoprost-solution-2","safety":{"commonSideEffects":[{"rate":"30-50%","effect":"Eyelid skin darkening"},{"rate":"10-20%","effect":"Eyelash growth"},{"rate":"5-10%","effect":"Itching"}]},"_chembl":{"chemblId":"CHEMBL1200963","moleculeType":"Small molecule","molecularWeight":"415.57"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Bimatoprost is a synthetic prostaglandin F2α analogue that acts as an agonist to the FP receptor, leading to increased uveoscleral outflow and decreased intraocular pressure.","oneSentence":"Prostaglandin F2α analogue","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:23:55.914Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Glaucoma"},{"name":"Ocular hypertension"}]},"trialDetails":[{"nctId":"NCT04499248","phase":"PHASE1, PHASE2","title":"AGN-193408 SR in the Treatment of Open-angle Glaucoma or Ocular Hypertension","status":"RECRUITING","sponsor":"AbbVie","startDate":"2020-11-16","conditions":"Open-angle Glaucoma, Ocular Hypertension","enrollment":96},{"nctId":"NCT06761313","phase":"PHASE4","title":"Triplenex (triple Fixed Combination) Use Evaluation in Patients with Glaucoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Federal University of São Paulo","startDate":"2021-03-01","conditions":"Glaucoma, Quality of Life (QOL)","enrollment":40},{"nctId":"NCT06267274","phase":"PHASE1","title":"A Randomized, Double-blind, Parallel-group, Two-arm, Multiple Dose, Multicenter, Bioequivalence Study With Clinical Endpoint in the Treatment of Subjects With Chronic Open-angle Glaucoma or Ocular Hypertension in Both Eyes","status":"RECRUITING","sponsor":"Amneal Pharmaceuticals, LLC","startDate":"2024-04-01","conditions":"Open-angle Glaucoma, Ocular Hypertension","enrollment":240},{"nctId":"NCT04890106","phase":"PHASE3","title":"Bioequivalence Study With Clinical Endpoint Comparing Bimatoprost Ophthalmic Solution 0.01% to LUMIGAN® In The Treatment of Chronic Open-Angle Glaucoma","status":"COMPLETED","sponsor":"Mankind Pharma Limited","startDate":"2021-10-02","conditions":"Glaucoma, Open-Angle","enrollment":310},{"nctId":"NCT05401357","phase":"PHASE3","title":"Bioequivalence Study With Clinical Endpoint Comparing Bimatoprost Ophthalmic Solution 0.01% and LUMIGAN® in the Treatment of Chronic Open-Angle Glaucoma or Ocular Hypertension in Both Eyes.","status":"RECRUITING","sponsor":"Amneal Pharmaceuticals, LLC","startDate":"2022-06-29","conditions":"Glaucoma, Open-Angle, Ocular Hypertension","enrollment":168},{"nctId":"NCT02358369","phase":"PHASE2","title":"Dose-Ranging Study of the Bimatoprost Ocular Insert","status":"COMPLETED","sponsor":"ForSight Vision5, Inc.","startDate":"2015-01-19","conditions":"Primary Open-Angle Glaucoma, Ocular Hypertension","enrollment":156},{"nctId":"NCT01157364","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of a New Ophthalmic Formulation of Bimatoprost in Patients With Open Angle Glaucoma and Ocular Hypertension","status":"COMPLETED","sponsor":"Allergan","startDate":"2010-09-23","conditions":"Open-Angle Glaucoma, Ocular Hypertension","enrollment":109},{"nctId":"NCT02448043","phase":"NA","title":"Cutaneous Prostaglandin Application: Nail Growth, Nail Brittleness, and Eye Pressure","status":"COMPLETED","sponsor":"Northwestern University","startDate":"2015-06-04","conditions":"Nail Growth Cessation, Intraocular Pressure","enrollment":45},{"nctId":"NCT03966560","phase":"PHASE4","title":"Choroidal Thickness and Its Correlations With Ocular Parameters in Primary Open-angle Glaucoma","status":"COMPLETED","sponsor":"Afyon Kocatepe University Hospital","startDate":"2014-01","conditions":"Glaucoma, Open-Angle","enrollment":96},{"nctId":"NCT00440011","phase":"PHASE4","title":"Bimatoprost 0.03% Versus Travoprost 0.004% in Patients Currently on Latanoprost 0.005%","status":"COMPLETED","sponsor":"Allergan","startDate":"2006-08","conditions":"Glaucoma, Ocular Hypertension","enrollment":266},{"nctId":"NCT01170884","phase":"PHASE4","title":"Comparing Safety and Efficacy of Combigan® and Lumigan® With Lumigan® Alone in Glaucoma or Ocular Hypertension Subjects Treated With Xalatan®","status":"COMPLETED","sponsor":"Allergan","startDate":"2009-12","conditions":"Glaucoma, Ocular Hypertension","enrollment":121},{"nctId":"NCT00539526","phase":"PHASE4","title":"Evaluation of Hyperemia With the Use of Ocular Prostaglandin Analogues","status":"COMPLETED","sponsor":"Allergan","startDate":"2007-09","conditions":"Open Angle Glaucoma, Ocular Hypertension","enrollment":106},{"nctId":"NCT01068964","phase":"NA","title":"Safety and Efficacy of Bimatoprost Timolol Ophthalmic Solution in Patients With Open Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Allergan","startDate":"2010-02-01","conditions":"Open-angle Glaucoma, Ocular Hypertension","enrollment":235},{"nctId":"NCT02419508","phase":"PHASE4","title":"SIMBRINZA® Suspension BID as an Adjunctive to Prostaglandin Analogue (PGA)","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2015-08-07","conditions":"Open-Angle Glaucoma, Ocular Hypertension","enrollment":290},{"nctId":"NCT01298700","phase":"PHASE4","title":"Long-Term Safety of Bimatoprost Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Allergan","startDate":"2011-05-31","conditions":"Glaucoma, Ocular Hypertension","enrollment":806},{"nctId":"NCT02863705","phase":"PHASE4","title":"Efficacy and Safety of COMBIGAN® in Korean Patients With Primary Open Angle Glaucoma (POAG) and Normal Tension Glaucoma (NTG)","status":"COMPLETED","sponsor":"Allergan","startDate":"2016-07-05","conditions":"Glaucoma, Open-Angle, Normal Tension Glaucoma","enrollment":118},{"nctId":"NCT01915940","phase":"PHASE2","title":"Bimatoprost Ocular Insert Compared to Topical Timolol Solution in Patients With Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"ForSight Vision5, Inc.","startDate":"2013-10-23","conditions":"Primary Open-Angle Glaucoma, Ocular Hypertension","enrollment":169},{"nctId":"NCT03487042","phase":"PHASE4","title":"Bimatoprost 0.03% Solution With NB-UVB Versus Their Use With Fractional Carbon Dioxide Laser in Treatment of Generalized Vitiligo","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2018-05","conditions":"Generalized Vitiligo","enrollment":40},{"nctId":"NCT02676310","phase":"PHASE1","title":"Safety, Tolerability, and Pharmacokinetics of Bimatoprost in Men With Androgenetic Alopecia (AGA)","status":"TERMINATED","sponsor":"Allergan","startDate":"2016-03","conditions":"Alopecia, Alopecia, Androgenetic, Baldness","enrollment":53},{"nctId":"NCT01217606","phase":"PHASE3","title":"Safety and Efficacy of Triple Combination Therapy in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Allergan","startDate":"2011-01","conditions":"Glaucoma, Open-Angle, Ocular Hypertension","enrollment":185},{"nctId":"NCT02059655","phase":"PHASE4","title":"Prostaglandin F2-alpha Eye Drops in Thyroid Eye Disease (Bima Study)","status":"COMPLETED","sponsor":"Cardiff University","startDate":"2014-11","conditions":"Graves' Ophthalmopathy","enrollment":31},{"nctId":"NCT01904721","phase":"PHASE2","title":"A Safety and Efficacy Study of Bimatoprost in Men With Androgenic Alopecia (AGA)","status":"COMPLETED","sponsor":"Allergan","startDate":"2013-08","conditions":"Alopecia, Alopecia, Androgenetic, Baldness","enrollment":244},{"nctId":"NCT01863953","phase":"PHASE2","title":"A Safety and Efficacy Study of Fixed-Combination Bimatoprost and Brimonidine in Chronic Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Allergan","startDate":"2013-06","conditions":"Glaucoma, Ocular Hypertension","enrollment":112},{"nctId":"NCT01241240","phase":"PHASE3","title":"Safety and Efficacy of Triple Combination Therapy in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Allergan","startDate":"2011-03","conditions":"Glaucoma, Open-Angle, Ocular Hypertension","enrollment":192},{"nctId":"NCT01110499","phase":"PHASE2","title":"Safety and Efficacy of AGN-210961 Ophthalmic Solution Compared With Bimatoprost Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Allergan","startDate":"2010-06","conditions":"Ocular Hypertension, Primary Open-Angle Glaucoma","enrollment":163},{"nctId":"NCT01325350","phase":"PHASE2","title":"Safety and Efficacy Study of Bimatoprost in the Treatment of Women With Female Pattern Hair Loss","status":"COMPLETED","sponsor":"Allergan","startDate":"2011-06","conditions":"Alopecia, Baldness","enrollment":306},{"nctId":"NCT01291108","phase":"PHASE2","title":"Safety and Efficacy of AGN-210669 Ophthalmic Solution Compared With Bimatoprost Ophthalmic Solution in Patients With Open-Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Allergan","startDate":"2011-04","conditions":"Glaucoma, Open-Angle, Ocular Hypertension","enrollment":125},{"nctId":"NCT00693420","phase":"PHASE3","title":"Safety and Efficacy of Bimatoprost Solution in Increasing Overall Eyelash Prominence","status":"COMPLETED","sponsor":"Allergan","startDate":"2007-04","conditions":"Eyelashes","enrollment":278},{"nctId":"NCT00809848","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of AGN 210669 Ophthalmic Solution in Patients With Ocular Hypertension or Primary Open-Angle Glaucoma","status":"COMPLETED","sponsor":"Allergan","startDate":"2009-02","conditions":"Ocular Hypertension, Glaucoma","enrollment":172},{"nctId":"NCT00907426","phase":"PHASE3","title":"Safety and Efficacy Study of Bimatoprost to Treat Hypotrichosis of the Eyelashes After Application to the Eyelid Margin","status":"COMPLETED","sponsor":"Allergan","startDate":"2009-08","conditions":"Hypotrichosis","enrollment":368},{"nctId":"NCT01255306","phase":"","title":"The Influence of Silicone Oil on Nerve Fiber Layer Thickness After Pars Plana Vitrectomy","status":"COMPLETED","sponsor":"University Hospital Sestre Milosrdnice","startDate":"2010-04","conditions":"Rhegmatogenous Retinal Detachment, Toxic Effect of Silicone, Glaucoma Due to Silicon Oil","enrollment":60},{"nctId":"NCT00541242","phase":"PHASE4","title":"Safety and Efficacy of Bimatoprost Compared With Latanoprost in Patients With Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Allergan","startDate":"2007-12","conditions":"Ocular Hypertension, Glaucoma","enrollment":586},{"nctId":"NCT00651859","phase":"PHASE2","title":"Safety and Efficacy Study of Bimatoprost in Ethnically Japanese Patients With Open-Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Allergan","startDate":"2002-11","conditions":"Glaucoma, Ocular Hypertension","enrollment":111},{"nctId":"NCT00652496","phase":"PHASE2","title":"Safety and Efficacy Study of Different Formulations of Bimatoprost Once-Daily in Patients With Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Allergan","startDate":"2005-01","conditions":"Glaucoma, Ocular Hypertension","enrollment":249}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"Bimatoprost Solution 2","genericName":"Bimatoprost Solution 2","companyName":"Allergan","companyId":"allergan","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Prostaglandin F2α analogue Used for Glaucoma, Ocular hypertension.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}